Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of the erythroid-specific enhancer region of BCL11A in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs). Methods We conducted an open-label, single-group, phase 3 study of exa-cel in patients 12 to 35 years of age with transfusion-dependent β-thalassemia and a β 0 /β 0 , β 0 /β 0 -like, or non–β 0 /β 0 -like genotype. CD34+ HSPCs were edited by means of CRISPR-Cas9 with a guide mRNA. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was transfusion independence, defined as a weighted average hemoglobin level of 9 g per deciliter or higher without red-cell transfusion for at least 12 consecutive months. Total and fetal hemoglobin concentrations and safety were also assessed. Results A total of 52 patients with transfusion-dependent β-thalassemia received exa-cel and were included in this prespecified interim analysis; the median follow-up was 20.4 months (range, 2.1 to 48.1). Neutrophils and platelets engrafted in each patient. Among the 35 patients with sufficient follow-up data for evaluation, transfusion independence occurred in 32 (91%; 95% confidence interval, 77 to 98; P<0.001 against the null hypothesis of a 50% response). During transfusion independence, the mean total hemoglobin level was 13.1 g per deciliter and the mean fetal hemoglobin level was 11.9 g per deciliter, and fetal hemoglobin had a pancellular distribution (≥94% of red cells). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No deaths or cancers occurred. Conclusions Treatment with exa-cel, preceded by myeloablation, resulted in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia. (Supported by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-111 ClinicalTrials.gov number, NCT03655678 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationBCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Cao, A., & Galanello, R. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cd68ed · Cited by 722
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Origa, R. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.173 · Cited by 509
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309676 · Cited by 493
Self-citationTaher, A. T., Musallam, K. M., & Cappellini, M. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2021838 · Cited by 477
Self-citationResults of Long-Term Iron-Chelating Therapy
Gabutti, V., & Piga, A. (2009) · Acta Haematologica · doi:10.1159/000203853 · Cited by 378
Corbacioglu, S., Carreras, E., Ansari, M., Balduzzi, A., Cesaro, S., Dalle, J.-H., Dignan, F., Gibson, B., Guengoer, T., Gruhn, B., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.161 · Cited by 363
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
Research works printed but not linked: 1
- Origa R. Beta-thalassemia. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews. Seattle: University of Washington, 1993.
Cited by
Items 101–200 of 245
Udeze, C., Gargano, M. A., Yang, H., Ogunsile, F. J., Li, N., Fang, H., Jeyakumar, S., & Lopez, A. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2649528 · Cited by 4
Recent Advances in Thalassemia Management: From Curative Therapies to Artificial Intelligence
Gamaleldin, M. M. A., Abdelhalim, S. M. N. S., & Abraham, I. L. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16020007 · Cited by 3
“In the phase 3 BELIEVE trial, a significantly higher proportion of patients receiving luspatercept achieved at least a 33% reduction in transfusion burden compared with placebo (21% vs. 4.5% over 12 weeks), with some patients achieving reductions exceeding 50% [28].”
InfluentialBradach, D., Calderón-Salavarría, K., Diaz‐Arribasplata, S., Almahdi, R. S. I., Mavus, N. B., Sangaraju, S. L., Sam, A. A., Mohamed, M. S., Brutus, C., Poojary, P. S., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70206 · Cited by 2
Non-genotoxic transplantation and in vivo selection through epitope editing
Casirati, G., Cosentino, A., Freschi, M., Zeng, J., Mucci, A., Levesque, S., Neri, N. R., Drago, E., Carzaniga, V., Romano, F., et al. (2026) · Nature · doi:10.1038/s41586-026-10737-8 · Cited by 6
Piel, F. B., de Montalembert, M., Das, R., Kuo, K. H. M., Taher, A. T., Musallam, K. M., Treadwell, M. J., Fucharoen, S., Angastiniotis, M., Higgs, D. R., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00722-w · Cited by 5
Self-citationShe, L., Liang, Z., Zou, Q., & Huo, Y. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00386 · Cited by 2
Poston, J. N., Andrews, J. C., Arya, S., et al. (2024) · Transfusion · doi:10.1111/trf.17975 · Cited by 2
Pediatric Advances in Gene Therapies for Hemoglobinopathies
Thompson, C., Ferdjallah, A., & Gupta, A. O. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.5366 · Cited by 2
Successful treatment of transfusion-dependent β-thalassemia: multiple paths to reach potential cure
Morgan, M. A., & Schambach, A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02135-9 · Cited by 3
Chiong, M. A. D., & Basas, A. A. (2025) · Journal of Religion and Health · doi:10.1007/s10943-025-02318-2 · Cited by 2
“The same treatment resulted in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia (Locatelli et al., 2024).”
Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support
Inam, Z. S., Han, H., Webb, J. L., & Delaney, M. (2025) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2025.150930 · Cited by 3
Joly, A., Schott, A., Phadke, I., González‐Menéndez, P., Kinet, S., & Taylor, N. N. (2024) · Physiology · doi:10.1152/physiol.00035.2024 · Cited by 3
Sichlinger, L., Reilly, M. B., Arora, S., Zhang, S., Marotta, N., Rodríguez-Acevedo, K. L., Hooks, M., Czarnecki, K. S., Winter, J. J., Waxman, E. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.28.685100 · Cited by 4
Sheth, S., Corbacioglu, S., de la Fuente, J., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70382 · Cited by 2
“In the Phase 3 CLIMB THAL-111 study of exa-cel in patients with TDT aged 12–35 years, infusion of exa-cel led to transfusion-independence in 91.4% of participants, with mean total hemoglobin in the normal range of 13.1 g/dL and mean HbF of 11.9 g/dL with pancellular distribution [14].”
InfluentialSelf-citationUne approche CRISPR/Cas pour traiter les β-hémoglobinopathies
Brusson, M., & Miccio, A. (2025) · médecine/sciences · doi:10.1051/medsci/2024191 · Cited by 3
Novel Therapeutic Advances in β-Thalassemia
Srichairatanakool, S., & Tantiworawit, A. (2025) · Journal of Hematology and Transfusion Medicine (วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต) · doi:10.69898/jhtm.35.2025.275741 · Cited by 1
The Changing Landscape of Opportunity for Cure of Severe Hemoglobinopathies in Middle-Income Regions
Faulkner, L. (2025) · Thalassemia Reports · doi:10.3390/thalassrep15010003 · Cited by 1
“Techniques like gene addition using lentiviral vectors [13] and genome editing via CRISPR/Cas9 [14] have shown promise in clinical trials, with patients achieving transfusion independence and relief from severe symptoms.”
Crowe, E. P., Andrews, J. C., Chou, S. T., et al. (2025) · Transfusion · doi:10.1111/trf.18330 · Cited by 1
CURE Asthma: a unique opportunity for Australia
Flynn, A. W. P., Edmondson, W., James, A., Lodge, C., McDonald, V. M., Jenkins, C. R., Blakey, J., & Anderson, G. P. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.70093 · Cited by 1
Shan, X., Li, Q., Wang, M., Niu, Y., Sun, Z., Ma, X., Wang, T., Tong, X., Zhang, J., & Niu, D. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01756-1 · Cited by 1
Hara, Y., Lemgart, V. T., Lessard, S., Mercadante, C. J., Ribeil, J., Hicks, A., Rimmelé, P., & Light, D. R. (2025) · Science Advances · doi:10.1126/sciadv.adx1144 · Cited by 1
Jang, Y., Eom, Y. J., Gwak, S.-H., Koh, Y., Han, J., Rim, Y. A., Nam, Y., & Ju, J. H. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04825-1 · Cited by 3
Emerging Considerations in Transfusion Medicine
Gibson, N. M., Kwiatkowski, J. L., & Chou, S. T. (2025) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2025.10.006 · Cited by 1
Self-citationHbF-inducing gene therapies for the β-hemoglobinopathies: implications for future pregnancies
Gavillet, M., Legardeur, H., Adam, C. J. M., Renella, R., Dashraath, P., & Baud, D. (2026) · Blood Red Cells & Iron · doi:10.1016/j.brci.2026.100047 · Cited by 2
Gab-Obinna, C. L., Oriaku, I., Okeoma, O. I., Olowookere, A. K., Obong, E. E., Onyedum, N. N., & Bala, J. I. (2026) · Australian Journal of Biomedical Research · doi:10.63946/aubiomed/17736 · Cited by 2
Nualkaew, T., Pongpaksupasin, P., Munkongdee, T., Buasuwan, N., Paiboonsukwong, K., Sripichai, O., Engel, J. D., Hongeng, S., Fucharoen, S., & Jearawiriyapaisarn, N. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01421-8 · Cited by 1
“…gene addition (Kwiatkowski et al. 2024; Locatelli et al. 2022) and CRISPR-Cas9 mediated genome editing to induce fetal hemoglobin (HbF; α 2 γ 2 ) (Locatelli et al. 2024), have been approved by the U.S. Food and Drug Administration (FDA) and have shown promising outcomes, with nearly all…”
Wang, M., Zhou, T., Liu, S., Xiang, W., Xie, K., Zhang, X., Hu, W., Fang, M., Zhang, Z., Chen, M., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1715984 · Cited by 3
Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders
Winkler, R., Herath, I., Kaczmarek, R., Xiao, W., Herzog, R. W., & Severeid, P. (2026) · Journal of Blood Medicine · doi:10.2147/jbm.s576017 · Cited by 3
“86 As betibeglogene autotemcel continues to be utilized in the clinical setting, it will be of interest to study the effectiveness and practicality of its use as a treatment option to potentially replace current treatment regimens, especially in relation to its affordability for affected patients.”
Cardiovascular Science, Medicine, and Society: The Brave New World
Regan, J. A., Laitner, M. H., & Dzau, V. J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.085 · Cited by 3
CRISPR in Thalassemia: Global Research Trend Analysis
Saboor, M., Alblooshi, M. J., Alkaabi, A. A., Soozaei, F. R., & Alketbi, M. H. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2634815 · Cited by 1
Shariati, A., Homaei, A., Khezrpour, A., Azizi, N., Khani, P., Shariati, F. S., Rafiee, M., Afkhami, H., Yousefi, M. H., Saeidi, F., et al. (2026) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2026.100382 · Cited by 1
Current therapeutic landscape of β-thalassemia: focus on gene therapy
Cheng, A. N., & Kwiatkowski, J. L. (2026) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040261433028 · Cited by 4
Self-citationClinical translation of epigenome editing technologies
Ma, A. J., Brown, B. H., Kim, S., & Hilton, I. B. (2026) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2026.100666 · Cited by 3
Nanopore third-generation sequencing for the diagnosis of rare hemoglobinopathies in Southern China
Lin, F., Yang, S.-X., Ge, Y.-Y., Yang, Y., Xie, L.-X., & Yang, L. (2026) · Journal of Human Genetics · doi:10.1038/s10038-026-01477-8 · Cited by 1
“Gene therapy represents a new direction for future thalassemia treatment [4, 5].”
CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics
Grigg, S. E., Shembrey, C., Fareh, M., Blombery, P. A., Corn, J. E., Seymour, J. F., & Casan, J. M. L. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01179-2 · Cited by 5
Base editing for precision therapeutics
Regmi, M., Ma, K., Bi, C., Zhang, X., Zhao, D., Yu, L., Huihui, Y., Wang, N., & Yang, C. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101298 · Cited by 2
Elsabbagh, E. M., Shawky, A. A., & Dvorak, C. C. (2026) · Pediatric Annals · doi:10.3928/19382359-20260628-01 · Cited by 1
Clinical base editing for β-hemoglobinopathies across different genetic backgrounds
Liu, R., Lai, Y., Wang, L., Qian, X., Ma, X.-K., Li, Y., Yang, G., Shi, L., Li, Z., Wei, J., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.08.009 · Cited by 4
The expanding therapeutic landscape of β-thalassaemia
Musallam, K. M., Sheth, S., Locatelli, F., Shah, F., Rivella, S., Kuo, K. H. M., Forni, G. L., Kattamis, A., Aydınok, Y., Glenthøj, A. B., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00173-0 · Cited by 3
Self-citationMechanistic and Biological Perspectives on Erythropoiesis
Bresnick, E. H., Papayannopoulou, T., & Migliaccio, A. R. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104286 · Cited by 1
All-in-one gene therapy alternative for DBAS
Navarro, S., & Rı́o, P. (2025) · Cell stem cell · doi:10.1016/j.stem.2024.12.003 · Cited by 1
Gomez‐Ospina, N., Vera, L. P., Gastou, M., Colella, P., Basurto, J. A., Feng, A., Lin, Y., Zhao, X., & Sun, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7123212/v1 · Cited by 1
Ventura, A. (2024) · Medico e Bambino · doi:10.53126/meb43349
Fibrillarin modulates fetal hemoglobin silencingPreprint
Wu, D., Li, Q., Qiu, S., Guo, C., Li, F., Shangguan, W., Li, W., Yang, D., Meng, X., Xing, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.25.600532
Studies of Exagamglogene Autotemcel — Age and Place
Frangoul, H., Hobbs, W. E., & Locatelli, F. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2407381
Self-citation… und schon wieder eine neue Ära?
Schrezenmeier, H. (2024) · Transfusionsmedizin · doi:10.1055/a-2138-6451
Exagamglogen-Autotemcel bei transfusionsabhängiger Beta-Thalassämie
Lorenz, J. (2024) · Pädiatrie up2date · doi:10.1055/a-2358-7236
Classical Haematology: Dynamic Development at the Interface of Transfusion Medicine and Haematology
Schrezenmeier, H. (2024) · Transfusion Medicine and Hemotherapy · doi:10.1159/000540110
Revisiting γ-globin gene repression by TR4
Perkins, A. C. (2024) · Blood · doi:10.1182/blood.2024026481
CRISPR: fundamental principles and implications for anaesthesia
Perez, A. R., Mavrothalassitis, O., Chen, J. S., Hellman, J., & Gropper, M. A. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.11.040 · Cited by 1
Two is better than one: Advancing gene therapy protocols for enhanced safety and efficacy
Hardouin, G., & Miccio, A. (2025) · Cell stem cell · doi:10.1016/j.stem.2024.12.009
Clinical applications of gene editing and therapy
Badat, M., & Davies, J. O. J. (2025) · Wiley eBooks · doi:10.1002/9781119706687.ch7
A Brief History of Pediatrics and the Beginnings of Pediatric Engineering
Phoon, C. K. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-84655-7_1
Killer, M. C., Zhang, X., Adhikary, T., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6470951/v1
HLA antibodies delay platelet recovery after gene therapy
Gupta, A. O., & Sharma, A. (2025) · Blood · doi:10.1182/blood.2025028995
CRISPR/Cas gene editing of haematopoietic stem cells for curing primary immunodeficiency
Bak, R. O., Holm, M., Møller, B. K., Mikkelsen, J. G., & Mogensen, T. H. (2025) · Ugeskrift for Læger · doi:10.61409/v02250083
CRISPR as a functional cure for hemoglobinopathies
Glenthøj, A. B., Carlsen, S. B. I. S., Hoffmann, M. H., Haastrup, E. K., Andersen, L. P., Toft, N., Kornblit, B. T., Petersen, J., Hasle, H., & Ifversen, M. (2025) · Ugeskrift for Læger · doi:10.61409/v12240888
Gene Therapy & Gene-Editing Techniques
LaRocca, C. J., & Steer, C. J. (2025) · Success in academic surgery · doi:10.1007/978-3-031-83034-1_13
A Multicenter Retrospective Study of HbH in China Including 1421 Patients Over a 12‐Year Timespan
Shang, H., Xu, S., Zhang, Y., Liang, J., Li, P., Zeng, L., Gu, Y., Li, H., Wei, W., Lu, Z., et al. (2025) · eJHaem · doi:10.1002/jha2.70087 · Cited by 1
Balusu, R., Soder, R. P., Dudley, N. R., McGuirk, J. P., & Abhyankar, S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.027
Hardouin, G., Martinucci, P., Scaramuzza, S., Antoniou, P., Corradi, F., Tachtsidi, A., Corre, G., Mombled, M., Manceau, S., Rouillon, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.21.671453
Ethical and Legal Dimensions of Access to CRISPR Technologies in Rare Disease Therapies
Telli, K., Özdemir, B., Danışman, S., & Yücesan, E. (2025) · Genetics. · doi:10.5772/intechopen.1012213
Khamphikham, P., Tantiworawit, A., & Anuchapreeda, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333127 · Cited by 1
“One approach aims to mitigate excess α -globin toxicity by reactivating γ -globin expression postna-tally, thereby restoring globin balance through increased production of fetal hemoglobin (HbF, α 2 γ 2 ) [8,9].”
Benítez‐Carabante, M. I., Lopez, A. M., Oficialdegui, M. L. U., Beléndez, C., Romero, M. P., Plaza, M., Fuentes, C., Enríquez, S. V., Silva, G. G., López‐Duarte, M., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.09.012
Enhancing Biotechnological Applications Using an Optimized Semiconductor Refrigeration Device
Zhang, G., Li, Y., Pang, H., Tu, Q., & Wang, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c11150
El-Khalifa, B. M., Soliman, W. A., Mazy, H. M., Ahmed, M. G., Al-Trad, H., Elmeneizee, T. H., El-Aziz, H. W. A., Abdelmutaleb, S. A. H., Abdelghaffar, G. A., & Morsi, M. H. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00806-4 · Cited by 4
Vermersch, A., Gervaise, C., Rascle, P., Laflotte, A., Tawil, S., Delpech, L., Schwiertz, V., & Bréant, V. (2025) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2025.12.003
Sickle cell disease and thalassemia go to the PROm
Abboud, M. R., & Andemariam, B. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017436
Digioia, D., Nguyen, T., Perepu, U., et al. (2025) · Oral and Maxillofacial Surgery Cases · doi:10.1016/j.omsc.2025.100431
Disrupting epigenetic insulation underlies CRISPR therapy for β-hemoglobinopathies
Wang, K., Wang, J., Weiss, M. J., Yue, F., & Xu, J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.015
Biard, L., Lévy, V., Chevret, S., Künkele, A., Grunwald, S., Aiuti, A., Møller, B. K., Debets, R., Mielke, S., Eldere, J. V., et al. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201651 · Cited by 1
Transcription factor binding to the γ-globin promoter regulates the γ-to-β-globin switch
Wei, X.-R., Huang, X.-H., Liu, S.-E., Zhao, Y.-J., Chen, M., Jin, D., Gao, Y., Zhang, Y.-H., Ai, H.-X., Ma, Y.-L., et al. (2026) · Reproductive and Developmental Medicine · doi:10.1097/rd9.0000000000000151
Zhang, T., Wang, Y., Shi, C., Zi, Y., Cai, W., & Zhong, J. (2026) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2025.01075 · Cited by 1
Frangoul, H., McManus, M. P., Carroll, C., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.12.037
Self-citationLDB1 represses fetal hemoglobin expression by enhancing BCL11A transcription
Park, S.-W., Choi, C., Park, I.-B., Kang, S. J., Lee, H. J., Kim, J.-I., Bae, J., Geum, D., Cheon, Y. P., & Chun, T. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104070
Synergistic integration of inducible RNA switches enhances the manipulation of vector expressionPreprint
Zhang, Y., Yang, Y., Liu, Z., Li, Y., Xue, Y., Zhang, Z., Chen, G., Lu, T., Zhang, Y., Zhao, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.06.704328
Matthes, J. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_8
Novel therapeutics in autism spectrum disorder
Kevelson, S. D., Elmaghraby, R., Patel, F., Brown, H. R., Gorenstein, M., Bain, J., Grinspan, Z. M., Pedapati, E. V., Veenstra-VanderWeele, J. M., & Vandana, P. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00857 · Cited by 7
“Phase 3 trials demonstrated substantial reductions in vaso-occlusive crises for people with sickle cell disease [207] and transfusion dependence in people with beta-thalassemia [208].”
AlMoshary, M., Qushmaq, N. A., Elgujja, A. A., Alamoudi, A., Alqahtani, M. S., Bugshan, H. S., Antony, M., & Alshahrani, F. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s556083
mRNA therapy: A novel approach for retinal neurodegenerative diseases
Zhang, B., Tang, J., Zhang, Q., Qiu, Y., Cheng, Y., Yu, S., Liu, L., Xue, J., Liu, X., He, Q., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-01306 · Cited by 3
Shin, E. J., Choi, Y., Jeon, E. J., Lee, K.-I., Lee, K.-J., Son, Y. J., Son, M. J., Kim, S., Cho, S., & Lee, J. Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.005 · Cited by 1
Genetic influences on haematopoiesis
Poeschla, M., & Sankaran, V. G. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-00947-1 · Cited by 3
Targeting enhancer RNAs to silence transcription
Perkins, A. C. (2026) · Blood · doi:10.1182/blood.2025032076
Ye, T., Xu, W., Barrachina, M. N., Lyu, P., Antoszewski, M., della Volpe, L., Guo, C., Lee, A., Villalpando, E., Johnson, I. A., et al. (2026) · Cell stem cell · doi:10.64898/2026.03.27.714536
Genome and epigenome editing approaches to treat β-hemoglobinopathies
Fontana, L. (2024) · theses.fr (ABES) · doi:10.70675/f1623d8bz5529z4d2dzb255z45ed273f643c
Cohrt, K. O., & O’Dea, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083384
“Of all enrolled patients, 97% achieved transfusion independence, with hemoglobin levels maintained predominantly through durable HbF induction [20].”
Jia, K., Soupène, E., Sinha, R., Lesch, B. J., Pendergast, M. A., Choi, R., Zhang, X., Foppiani, E. M., Kostamo, Z., Chu, S. N., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.13.718029
Immune Effector Cell and Gene Therapies in Pediatric Critical Care
Ragoonanan, D. S., & Mahadeo, K. M. (2026) · Springer eBooks · doi:10.1007/978-3-319-74698-2_200-2
Novel phosphatase-based regulatory loop for HbF expression
Franceschi, L. D. (2026) · Blood · doi:10.1182/blood.2025032772
Khare, G., Duong, A., Hanotaux, J., Shorr, R., Nampoothiri, R. V., Maganti, H. B., & Allan, D. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102898 · Cited by 1
Different Types of Gene Therapy
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_2
Arji, S., Shen, Z., Welch, S., ElMahdaoui, F., Bahadur, A., Lee, E., Lee, H., Wu, S.-C. P., Konshina, E., Ayubali, B., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00911-5 · Cited by 1
Özkan, İ., Kılıç, K. M., & Taylan, S. (2026) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2026.04.023
Is gene therapy a cure for β-thalassemia?
Frangoul, H. (2026) · Blood · doi:10.1182/blood.2025032609
Self-citationManufacturing Cell-Based Products
Lorenzo, N. L., Vilariño, L. B., & Baliu‐Piqué, M. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_28
Piroozan, Y., Arabshahi, A., Akbar-Abad, M. S., Majidpour, M., Pazouki, M. M., Shahriari, H., Naderi, M., Abbasi‐Malati, Z., & Azizi, S. G. (2026) · Research Square · doi:10.21203/rs.3.rs-9820820/v1
Charting the computational landscape of single-cell genetic perturbation
Zhang, Y., Huang, J., Li, Y., Liu, T., Ren, L., Huang, J. H., Lin, H., Feng, J., & Zhang, Y. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.06.012 · Cited by 1
Soliman, A. T., Alyafei, F., Alaaraj, N., Hamed, N., Ahmed, S., & Elawwa, A. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030018 · Cited by 1
Minaiyan, G., Aussel, C., Ammann, S., & Cathomen, T. (2026) · Human Gene Therapy · doi:10.1177/10430342261465555
Sharma, A., & Corbacioglu, S. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019856
Self-citation
Metadata
- Authors
- Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., Mapara, M., Liem, R. I., Cappellini, M. D., Algeri, M., Kattamis, A., Sheth, S., Grupp, S., Handgretinger, R., Kohli, P., Shi, D., Ross, L., Bobruff, Y., Simard, C., Zhang, L., Morrow, P. K., Hobbs, W. E., & Frangoul, H.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From IRCCS Ospedale Pediatrico Bambino Gesù (F.L., M.A.) and Catholic University of the Sacred Heart (F.L.), Rome, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (M.D.C.), and the Department of Health Sciences, Magna Graecia University, Catanzaro (M.A.) — all in Italy; University Children’s Hospital Tübingen (R.H.), and the Cluster of Excellence iFIT (EXC 2180) “Image-guided and Functionally Instructed Tumor Therapies” and the German Cancer Consortium, Partner Site Tübingen, University of Tübingen (P.L.), Tübingen, the Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf (R.M.), and the University of Regensburg, Regensburg (S.C.) — all in Germany; the Hospital for Sick Children and University of Toronto, Toronto (D.W.), and BC Children’s Hospital, University of British Columbia, Vancouver (A.M.L.) — all in Canada; Imperial College Healthcare NHS Trust, St. Mary’s Hospital (J.F...
- ORCID
- Locatelli, Franco
- Lang, Peter
- Wall, Donna
- Meisel, Roland
- Corbacioglu, Selim
- Li, Amanda M.
- Shah, Ami J.
- Carpenter, Ben
- Kwiatkowski, Janet L.
- Mapara, Markus
- Liem, Robert I.
- Cappellini, Maria Domenica
- Algeri, Mattia
- Kattamis, Antonis
- Sheth, Sujit
- Grupp, Stephan
- Handgretinger, Rupert
- Kohli, Puja
- Zhang, Lanju
- Morrow, Phuong Khanh
- Frangoul, Haydar
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-09
- Volume
- 390
- Issue
- 18
- Pages
- 1663-1676
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4395068362
- Cited by
- 253
- References
- 35
- Citations by year
- 2026: 128 · 2025: 89 · 2024: 35
- FWCI
- 70.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- CRISPR Therapeutics
- Vertex Pharmaceuticals
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- exagamglogene autotemcel, beta-thalassemia, CRISPR/Cas9 genome editing, BCL11A, fetal hemoglobin, hematopoietic stem cell transplantation, myeloablative conditioning, busulfan, transfusion independence, non-viral gene therapy, autologous hematopoietic stem cells
- MeSH terms
- Gene Editing, Adolescent, Adult, Blood Transfusion, Busulfan, Child, Europe, Female, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Male, North America, Repressor Proteins, Transplantation, Autologous, beta-Thalassemia, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Transplantation Conditioning, Myeloablative Agonists, Young Adult, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.